HIV expert Linda-Gail Bekker talks to The Conversation Weekly about promising results from a trial of a new drug for HIV prevention.
Academic rigour, journalistic flair
Articles on HIV prevention
Displaying 1 - 20 of 46 articles
PrEP can reduce the risk of sexually transmitted HIV infection by 99%. Discrimination and distrust are two barriers Black gay men face in accessing this lifesaving treatment.
Despite higher than average rates of HIV infection, Hispanic women have relatively low awareness of PrEP, an effective HIV-prevention medication.
Funding announced in this week’s federal budget moves Australia closer to eliminating HIV.
Sex workers have a deep understanding of their needs but development partnerships tend to prioritise scientific knowledge.
Many people at heightened risk for HIV have never been tested. Those who have self-tested for HIV often don’t go on to receive care or change their sexual behavior.
The next step in HIV prevention — long-acting injectable pre-exposure prophylaxis (PrEP) — is not yet available in Canada, a year after its approval in the U.S.
The benefit of an injectable product is that it avoids the adherence issues related to taking a pill daily.
Some countries, like Kenya, Uganda, South Africa, Zambia, and Nigeria, have been more proactive than others, but it is still hard for many to get PrEP.
The omission of growing evidence that Māori, and Māori women in particular, have worse health outcomes after HIV infection could derail New Zealand’s elimination plans and exacerbate disparities.
PrEP enables adolescent girls and young women to protect themselves from HIV without having to convince a partner to use a condom at the time of sex.
Difficult to understand communication and the somewhat overstated benefits of male circumcision may lead to increased risky sexual behaviour.
Facebook began blocking ads that linked Truvada and other HIV-related drugs to severe bone and kidney damage based on claims made in lawsuits.
Eradicating a virus from the community requires everyone to have access to prevention, as is the case with tuberculosis. So why not HIV?
In many parts of sub-Saharan Africa men who have sex with men encounter stigma and prejudice when accessing health services.
South Africa’s data rollout of its pre-exposure prophylaxis shows that there is a relatively slow, but increasing, uptake. However, more needs to be done to target young women.
Three new HIV vaccine concepts which rely on high-tech designer proteins are being trialled to see if they can stop the virus.
South Africa has made tremendous progress towards meeting the 90-90-90 targets but there are some challenges preventing it from reaching the goals set by UNAIDS.
The introduction of Pre Exposure Prophylaxis drugs in Kenya aims at reducing new HIV infections among people facing substantial ongoing risk.
At a time when a new national school curriculum is starting its pilot phase in Kenya, a study shows the massive gaps in sexuality education programmes.
Job Board
-
Executive Assistant to the Dean
-
Economics Editor
-
Deputy Vice-Chancellor (Indigenous Strategy and Services)
-
Chief People & Culture Officer
-
Lecturer / Senior Lecturer in Construction and Project Management
Top contributors
-
Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town
-
Senior lecturer, public health ethics, School of Population Health, UNSW Sydney
-
Associate Professor and Director: Research at the Wits Reproductive Health and HIV Institute I, University of the Witwatersrand
-
Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, University of the Witwatersrand
-
Assistant Professor of Public Health, University of Iowa
-
Director of Implementation Science, Wits Reproductive Health & HIV Institute, University of the Witwatersrand
-
Associate Professor and Principal Research Fellow, Australian Research Centre in Sex, Health and Society, La Trobe University
-
Assistant Professor of Marketing Weber State University, Weber State University
-
Honorary Senior Lecturer, School of Public Health, University of Cape Town
-
Associate Professor of Psychology, Indiana University
-
PhD candidate, Ghent University
-
Extraordinary Professor in the Department of Medical Microbiology, University of Pretoria
-
Director: Child & Adolescent Health at the Wits Reproductive Health and HIV Institute, University of the Witwatersrand
-
Director: Clinical Trials, Wits Reproductive Health and HIV Institute, University of the Witwatersrand
-
Assistant Professor of Global Health, Boston University
